Keywords: editor, views, astazeneca, exanta, woes, bayer/s-p, deal

Editor's views on AstaZeneca Exanta woes and Bayer/S-P deal

Article | 20 September 2004

Print This

It seems strange that AstraZeneca's new anticoagulant Exanta(ximelagatran) is safe and effective for European patients but not for those ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in